Conservative versus aggressive transurethral resection of bladder cancer for paraureteral bladder cancer: A comparison of postoperative ureteral stricture and cancer recurrence rates

保守性经尿道膀胱癌切除术与激进性经尿道膀胱癌切除术治疗输尿管旁膀胱癌:术后输尿管狭窄和癌症复发率的比较

阅读:1

Abstract

There are differing clinical perspectives on the resection range of transurethral resection of bladder tumor (TURBT) for paraureteral bladder cancer. This study aimed to compare the incidence of ureteral stricture and bladder cancer recurrence after conservative versus aggressive TURBT in the treatment of paraureteral bladder cancer. A retrospective analysis was performed on 164 patients with paraureteral bladder cancer who underwent TURBT between April 2017 and July 2024. Among them, 133 patients had complete clinical and follow-up data. Based on the resection margin of the tumor, patients were divided into the conservative group and the aggressive group. The 2 groups were compared regarding the outcomes of postoperative ureteral stricture and bladder cancer recurrence. The overall incidence of ureteral stricture within 1 year after TURBT was 11.28% (15/133), and the recurrence rate of bladder cancer was 21.80% (29/133). All patients had negative postoperative resection margins and no deaths within 1 year. The incidence of postoperative ureteral stricture was 11.11% (6/54) in the conservative treatment group and 11.39% (9/79) in the aggressive treatment group, with no statistically significant difference between the 2 groups (P = .960). The postoperative recurrence of bladder cancer was 31.48% (17/54) in the conservative treatment group and 15.19% (12/79) in the aggressive treatment group, and there was a statistically significant difference between the 2 groups (P = .025). Aggressive TURBT for paraureteral bladder cancer showed no significant difference in the incidence of postoperative ureteral stricture compared with conservative TURBT but significantly reduced the recurrence rate of bladder cancer. Therefore, we believe that during TURBT for paraureteral bladder cancer, maximizing the resection range, including a wider safety margin (>1 cm) around the main tumor - may be more appropriate.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。